Quotient Ltd (NASDAQ:QTNT)’s share price shot up 5.8% during mid-day trading on Wednesday . The company traded as high as $11.07 and last traded at $11.07. 605,650 shares were traded during mid-day trading, an increase of 55% from the average session volume of 389,578 shares. The stock had previously closed at $10.46.
A number of brokerages have recently issued reports on QTNT. ValuEngine upgraded shares of Quotient from a “hold” rating to a “buy” rating in a research note on Friday, January 11th. Zacks Investment Research cut shares of Quotient from a “hold” rating to a “sell” rating in a research note on Friday, November 9th. Finally, BidaskClub upgraded shares of Quotient from a “hold” rating to a “buy” rating in a research note on Tuesday, January 29th.
The company has a debt-to-equity ratio of 4.95, a quick ratio of 6.05 and a current ratio of 6.87. The company has a market cap of $671.12 million, a PE ratio of -5.29 and a beta of 1.31.
Quotient (NASDAQ:QTNT) last posted its earnings results on Thursday, January 31st. The company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.01). The firm had revenue of $6.72 million for the quarter, compared to analyst estimates of $6.20 million. On average, equities research analysts forecast that Quotient Ltd will post -1.93 earnings per share for the current year.
In other news, major shareholder Life Sciences Maste Perceptive bought 2,000,000 shares of the stock in a transaction dated Friday, December 7th. The shares were acquired at an average price of $6.50 per share, with a total value of $13,000,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Frederick Hallsworth bought 10,000 shares of the stock in a transaction dated Tuesday, December 11th. The stock was purchased at an average cost of $6.50 per share, for a total transaction of $65,000.00. Following the acquisition, the director now owns 55,091 shares in the company, valued at approximately $358,091.50. The disclosure for this purchase can be found here. 17.40% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Park West Asset Management LLC grew its holdings in shares of Quotient by 270.3% in the 4th quarter. Park West Asset Management LLC now owns 1,111,261 shares of the company’s stock worth $6,800,000 after purchasing an additional 811,174 shares during the last quarter. Diag Capital Management LP bought a new stake in shares of Quotient in the 4th quarter worth about $3,225,000. Highbridge Capital Management LLC grew its holdings in shares of Quotient by 47.5% in the 4th quarter. Highbridge Capital Management LLC now owns 3,003,433 shares of the company’s stock worth $18,382,000 after purchasing an additional 967,096 shares during the last quarter. Perceptive Advisors LLC grew its holdings in shares of Quotient by 22.8% in the 4th quarter. Perceptive Advisors LLC now owns 10,789,054 shares of the company’s stock worth $66,029,000 after purchasing an additional 2,000,000 shares during the last quarter. Finally, Polar Capital LLP grew its holdings in shares of Quotient by 8.6% in the 4th quarter. Polar Capital LLP now owns 5,796,063 shares of the company’s stock worth $35,472,000 after purchasing an additional 458,908 shares during the last quarter. 51.98% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Quotient (QTNT) Shares Up 5.8%” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://transcriptdaily.com/2019/03/01/quotient-qtnt-shares-up-5-8.html.
Quotient Company Profile (NASDAQ:QTNT)
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Featured Story: Yield Curve
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.